

27th July, 1982.

ROC/JDH

[REDACTED]  
Immoie Ltd.,  
Arctic House,  
Rye Lane,  
Dunton Green,  
Nr. Sevenoaks,  
Kent, TN14 5HB.

Dear Mr. [REDACTED],

Thank you so much for your offer to sponsor Mrs. [REDACTED]  
to attend the meeting of Social Workers in Newcastle.

In the event she was unable to go because of the rail strike  
but we are most grateful to you for your continuing support.

Yours sincerely,

[REDACTED],  
Senior Lecturer in Haematology.

# Immuno Ltd



Arctic House, Rye Lane, Dunton Green,  
Nr Sevenoaks, Kent TN14 5HB

Telephone: Sevenoaks (0732) 458101 & 450342  
Telex: 95413

Dr. [REDACTED]  
Senior Lecturer in Haematology,  
Haemophilia Centre,  
The London Hospital,  
Whitechapel,  
London.  
E1 1BB

25th June 1982  
PJC/GB

Dear Dr. [REDACTED],

Thank you for your letter dated 14th June 1982 enquiring about sponsorship for Mrs. [REDACTED] to attend the next meeting of the Haemophilia Group of the British Association of Social Workers in Newcastle. I can confirm that we will be pleased to offer sponsorship of £40 to enable Mrs. [REDACTED] to attend this meeting and I will be pleased if you can confirm the date of the meeting in due course.

It would be preferable for a claim to be made for this amount by the hospital so that a cheque can be made payable to the hospital or the Health Authority but if this is not possible a letter from you confirming that she will be attending the meeting would be sufficient and we would then make the cheque payable to Mrs. [REDACTED].

I look forward to hearing from you in due course.

Yours sincerely,  
for IMMUNO LTD.,

[REDACTED]  
[REDACTED]  
Marketing Director

14th June, 1982.

BTC/JDH

Marketing Manager,  
Immuno Ltd.,  
Arctic House,  
Rye Lane,  
Dunton Green,  
Nr. Sevenoaks,  
Kent, TN14 5HB.

Dear Mr. [REDACTED],

Thank you for your help with providing FEIBA for Mrs. [REDACTED]. I am pleased to report that so far the treatment has been successful and we must now hope that rebleeding does not occur.

As I discussed with you on the telephone I would be most grateful if Immuno could support the visit of our social worker, Mrs. [REDACTED], to the next meeting of the special interest group in haemophilia of the British Association of Social Workers. This will take place in Newcastle but as Mrs. [REDACTED] wants to go from London to Newcastle and then return to Sheffield the cost of her travel at £40 is rather less than the return fare from London to Newcastle.

Perhaps you would be kind enough to let me know whether Immuno might be willing to meet this cost and, if so, how you would like me to make a formal claim when the time comes.

With best wishes,

Yours sincerely,

[REDACTED]  
Senior Lecturer in Haematology.

# Immuno Ltd



Arctic House, Rye Lane, Dunton Green,  
Nr Sevenoaks, Kent TN14 5HB

Telephone: Sevenoaks (0732) 58101 & 50342  
Telex: 95413

Dr. [REDACTED],  
Department of Haematology,  
The London Hospital,  
Whitechapel Road,  
London. E1 1BB

1st April 1982  
PJC/GB

Dear Dr. [REDACTED],

North East Thames Regional Contract No. 72/009/239/81  
Stable Freeze Dried Factor V111 Concentrate  
Period: 1st April 1982 to 31st March 1983

We are pleased to inform you that we have, once again, been awarded a joint contract for the supply of Factor V111 concentrate to hospitals within the North East Thames Regional Health Authority. As from Thursday, 1st April 1982 all orders placed with us by your hospital for Kryobulin Blue Pack will be invoiced at 6p per unit irrespective of the quantity ordered. We will supply our product within the following ranges as specified within the contract:

Nominal 250 unit vial. Supplied within range of 230-250 iu  
Nominal 500 unit vial. Supplied within range of 460-500 iu  
Nominal 1000 unit vial. Supplied within range of 900-1000 iu

If it is found necessary to supply a batch above the maximum unitage then we will stand the cost of the extra units.

Please note that the reconstitution volumes for Kryobulin Blue Pack are as follows:

250 units in 10 ml  
500 units in 20 ml  
1000 units in 50 ml

We are enclosing details of the various packs which are available and we hope we will have the pleasure of supplying you with our product in the future.

Yours sincerely,  
for IMMUNO LTD.,

[REDACTED]  
Marketing Manager

Department of Haematology

27th May, 1982.

BTC/JDH

Dr. [REDACTED]  
Blood Products Laboratory,  
National Blood Transfusion Service,  
Dagger Lane,  
Elstree,  
Borehamwood,  
Herts, WD6 3DH.

HL:2873

Dear [REDACTED],

Thank you for your letter of May 12th about this batch of concentrate.

Both my junior medical staff and one of my home treatment patients confirm that the material takes a little longer to dissolve but it did not seem to worry them. They independently suggested that the interval was 8 - 10 minutes as opposed to 4 - 5 minutes for the standard material. My home treatment patient said he would be quite happy to use the concentrate at home. He did not seem bothered about being warned of the reduced solubility but I think the difference is sufficiently marked to justify giving the information.

With best wishes,

Yours sincerely,

[REDACTED]  
Senior Lecturer in Haematology.  
(Dictated by and signed in his absence).



## BLOOD PRODUCTS LABORATORY

National Blood Transfusion Service

Director:  
R.S. LANE, MD MRCP MRCPATH.  
Telephone : 01-953-6191

Dagger Lane,  
Elstree,  
Borehamwood,  
Herts WD6 3BX.

[REDACTED],  
The London Hospital,  
Turner Street,  
Whitechapel,  
London,  
E1 1BB

12th May, 1982.


Dear Dr. [REDACTED],

HL.2873

I am trying to follow up the use of a batch of factor VIII concentrate sent to you recently for precautionary clinical trial. As you may know, the British Pharmacopoeia requires that we test the solubility of batches of factor VIII at 20°C although we know that most users redissolve vials at 30-37°C and that our concentrate dissolves more rapidly at the higher temperature. Batch 2873 was found to be near the limits of compliance with the new B.P. description of 'solubility at 20 °C' and we asked you to try out a small number of vials which could be redissolved under controlled conditions in your clinic. We did not expect you to encounter any real difficulty but it is our policy to be very cautious in releasing any batch with the slightest unusual feature.

Perhaps you would now like to comment on some aspects of your experience with this batch :


- a) Have you had any real difficulty in redissolving this batch or any unusual clinical response?
- b) Have you found that, in practice, it takes significantly longer to redissolve than most other batches you receive from us?
- c) Would you now consider this batch as suitable for free issue for home therapy?



d) If so, would you wish us to add any information or practical advice to the pack?

You may wish simply to write comments on this letter and copy it to me in the enclosed envelope.

Yours sincerely,



Head of Quality Control.

14th October, 1961.

WTC/JDH

Dr. [REDACTED]  
Head, Coagulation Factors Department,  
National Blood Transfusion Service,  
Blood Products Laboratory,  
Bagger Lane,  
Elstree, Borehamwood,  
Herts, WD6 3EH.

Dear Dr. [REDACTED],

Thank you for your letter about intermediate factor VIII concentrate.

The whole of our allocation of IIS concentrate is in fact devoted to home treatment so that I can only use comparatively small amounts for other purposes if they are to be removed from my haemophilia allocation. There is usually some flexibility in the home treatment programme so that perhaps I could take one or two boxes a month of this product from you. If you wanted to give us a complete batch which would immediately neutralize the allocation for that month, this would very seriously disrupt the home treatment programme and make our life impossible. Could I therefore suggest that we either have small quantities of this material over a period of time, or that you ask another centre to take a large batch of material as they may have a different policy with regard to the distribution of Factor VIII.

Yours sincerely,

[REDACTED]  
Senior Lecturer in Haematology.





## BLOOD PRODUCTS LABORATORY

National Blood Transfusion Service

Director:  
R. S. LANE MD MRCPath.

Telephone: 01-953-6191

Dagger Lane,  
Elstree,  
Borehamwood,  
Herts WD6 3BX.

JKS/PP

5th October, 1981.

Dr. [REDACTED]  
The London Hospital,  
Turner Street,  
Whitechapel,  
LONDON, E1 1BB.

Dear Dr. [REDACTED],

### Intermediate Factor VIII Concentrate (HL)

We have recently produced a few batches which redissolve more slowly than usual. This is a consequence of small deviations in temperature control at the processing stage which affects only the compromise between protein concentration and factor VIII yield; all other control tests have given normal results. The product would have met our specification until earlier this year, when B.P. introduced a new limit on Specific Activity (units of factor VIII per mg protein) and we redefined the temperature for the solubility test as 20°. These batches fall just over or just under the limit of 20 minutes at 20°, and one falls marginally below the limit for Specific Activity.

We know that in practice this product is usually redissolved rapidly at a higher temperature, but feel that these batches might be better used in the Haemophilia Centres rather than issued for home therapy. I would be grateful if you would consider taking such product as part of your normal allocation, in which case I would arrange with your RTC to assign the batch to your Centre. If you wish further information, I would be glad to discuss it informally with you at the annual HC meeting on the 9th October, or to write with more details.

Yours sincerely,

[REDACTED]

[REDACTED]

Head, Coagulation Factors Department.

Department of Haematology

14th August, 1951.

BTC/JDH

Dr. [REDACTED]  
Director,  
Blood Products Laboratory,  
The Mitter Institute,  
Birstree,  
Herts.

Dear [REDACTED],

As I expect you are aware there is a growing demand for freeze dried fibrinogen for use in the removal of renal stones and I enclose copies of correspondence between Professor [REDACTED] and myself on this subject, and you will see that he feels that his department is likely to need about 30 bottles a year. You will also see that Professor [REDACTED] studied the technique in some detail and I am sure that a copy of our paper could be sent for you to look at if you think it would be helpful. You will also see that Professor [REDACTED] is willing to send you further details and photographs or discuss the problem with you personally.

Do you think that you will be able to meet the demand for this unusual but important use of fibrinogen? As far as know we have now used up all the available fibrinogen from the old production system and wonder when more will be available.

Yours sincerely,

[REDACTED]  
Senior Lecturer in Haematology.

c.c. Professor [REDACTED], Department of Urology,  
The London Hospital (Whitechapel).

# The London Hospital



---

Whitechapel London E1 1BB Telephone 01-247 5454

Department of Urology  
Professor J. P. Blandy. Extension 162.

4th August 1981

---

Dr [REDACTED],  
Senior Lecturer in Haematology  
LH (Whitechapel)

FIBRINOGEN FOR  
PYELOLITHOTOMY

Dear [REDACTED],

Thank you very much for your letter about the availability of Fibrinogen. Please forgive me for not replying earlier. We have found that Fibrinogen coagula have notably increased the safety and ease with which complete staghorn calculi may be removed. Owing to my own particular interest in these stones, we are likely to use coagulum about 30 times a year.

I enclose a xerox of the paper, in case you have not already got one, which [REDACTED] presented on our behalf at BAUS and it was very well received and it shows quite clearly that Fibrinogen is superior to cryoprecipitate.

Many workers from other centres have come to the Department to learn how to use this particular technique because the method evolved, thanks to your co-operation, by [REDACTED], has proved to be a notable advance on the standard one.

I expect that because of our work there will be an increased demand for Fibrinogen from other centres. It would therefore be most helpful if Dr Lane were able to produce enough Fibrinogen to meet this sort of demand. Do let me know if it would help for me to explain our needs to him personally: I would be delighted to do so.

PTO

Department of Haematology

13th June, 1981.

BTC/JDH

Mr. [REDACTED]  
Immuno Ltd.,  
Arctic House,  
Rye Lane,  
Dunton Green,  
Nr. Sevenoaks, Kent, TN14 5HD.

Dear Mr. [REDACTED],

Thank you very much for your cheque which was waiting for me when I returned from holiday. As you know the help given by your firm is much appreciated.

Yours sincerely,

[REDACTED],  
Senior Lecturer in Haematology.

20th May, 1981.

BTC/JDH/

Mr. [REDACTED],  
Marketing Executive,  
Imunoc Ltd.,  
Arctic House,  
Rye Lane,  
Dunton Green,  
Nr. Sevenoaks, Kent, TN14 5HB.

Social Work Conference  
in Manchester

Dear Mr. [REDACTED],

As agreed over the telephone last week I am now sending you the Access voucher for Ms [REDACTED] rail travel to Manchester to attend the conference on Social Work Aspects of Haemophilia. May I say how grateful we are to you for supporting her in this way. She enjoyed her day very much and will be submitting a written report to me in due course.

Would you be kind enough to make the cheque payable to The London Hospital Medical College, Department of Haematology. I believe this fits in with your policy and is very convenient from our point of view.

With best wishes and many thanks,

Yours sincerely,

[REDACTED],  
Senior Lecturer in Haematology.

Enc.